Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shandong Univ. HDAC8 compound 11k: sourced facts only. name: "Among them, the tetrahydroquinoline derivative 11k exhibited potent HDAC8 inhibitory activity (IC50 = 0.10 μM), and the indole derivative 5b also showed activity (IC50 = 0.28 μM), both with excellent selectivity." [PMID:41785528]; target: "Among them, the tetrahydroquinoline derivative 11k exhibited potent HDAC8 inhibitory activity (IC50 = 0.10 μM), and the indole derivative 5b also showed activity (IC50 = 0.28 μM), both with excellent selectivity." [PMID:41785528]; developer: "Department of Medicinal Chemistry, State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Shandong Key Laboratory of Druggability Optimization and Evaluation for Lead Compounds, Shandong Basic Science Academic Special Zone/ Research Center (Pharmacy), School of Pharmaceutical Sciences, Cheelo College of Medicine, Shandong University, Jinan, Shandong, PR China." [PMID:41785528]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shandong Univ. HDAC8 compound 11k.